Cambridge Healthtech Instituteの第4回年次
Next-Generation Immunotherapies
次世代の免疫療法
Novel Approaches for Reprogramming the Immune System
免疫系リプログラミング向け新規アプローチ
2025年5月15日 - 16日 EDT(米国東部標準時・夏時間)
Sunday, May 11
1:00 pmMain Conference Registration
2:00 pmRecommended Pre-Conference Short Course
SC3: Challenges and Opportunities in Solid Tumor and Autoimmune Disease Therapeutic Innovations
*Separate registration required. See short course page for details.
Tuesday, May 13
6:30 pmRecommended Dinner Short Course
SC5: Targeting the Target: Aligning Target and Biologic Format Biology to Achieve Desired Outcomes
*Separate registration required. See short course page for details.
Thursday, May 15
7:45 amRegistration and Morning Coffee
IN VIVO CAR T ENGINEERING: MOVING INTO THE CLINIC
In vivo mRNA-Based CAR T Cell Engineering for Treatment of B Cell Disorders
John Rossi, PhD, Vice President, Translational Medicine, Capstan Therapeutics
We developed a novel in vivo anti-CD19 CAR mRNA product (CPTX2309), delivered through CD8-targeted lipid nanoparticles (tLNP). Evaluation in non-human primates speaks to the potential of this platform to achieving immune reset, key to effectively treating B cell-autoimmunity. This sets up the stage for clinical development of CPTX2309 and opens an avenue for development of similar products for broad indications, overcoming the challenges of ex vivo viral-engineered CAR T cells.
In vivo and ex vivo Use of LNP-Mediated Technology to Treat Hematological Disorders
Stefano B. Rivella, PhD, Professor, Pediatrics, Children's Hospital of Philadelphia
Current therapies allow the replacement of diseased hematopoietic stem progenitor cells (HSPC) with gene-engineered or healthy HSPC through bone-marrow transplantation. Starting from ex vivo technologies, we will discuss how targeted lipid nanoparticles (tLNP) carrying messenger RNA (mRNA) can target HSPC and revolutionize how we perform bone-marrow transplantation or directly cure HSPC in vivo.

Speaker to be Announced, Sartorius
Bispecific antibodies (BsAbs) are therapeutic antibodies targeting different antigens or epitopes, enhancing potency and therapeutic effects. Various constructs, like scFv, DARTs, Triomabs, and BiTEs, are being developed for diseases like cancer. Their diverse designs may face structural constraints affecting binding and performance. A major challenge is the lack of technologies for quantitative functional assessment of BsAbs' dual targets, necessitating innovative approaches beyond traditional monoclonal antibodies. This talk will present solutions for efficient biophysical and functional characterization of BsAbs in development.
10:30 amCoffee Break in the Exhibit Hall with Poster Viewing
11:15 amTransition to Plenary Fireside Chat
PLENARY FIRESIDE CHAT
Riding the Next Biotech Wave-Trends in Biotech Investments, Partnering, and M&As
Jakob Dupont, MD, Executive Partner, Sofinnova Investments
- Emerging Biotherapeutic Modalities, Technologies and Innovations- ADCs, radiopharmaceuticals, GLP-1, AI, machine learning, and other exciting trends to watch
- Introduction to different strategies for investments, M&As, partnering, licensing etc.
- Investing in platforms versus assets
- Advice on funding options for start-ups, early to late stage clinical programs, etc.
12:25 pmLuncheon in the Exhibit Hall and Last Chance for Poster Viewing
NEXT-GENERATION IMMUNOTHERAPIES: IN VIVO APPROACHES
Increasing the Availability of CAR T Cells
Frederic B. Thalheimer, PhD, Molecular Biotechnology & Gene Therapy, Paul Ehrlich Institut
This presentation focusses on two upcoming strategies facilitating CAR T cell generation. Short-term CAR T cells accelerate production times but may bear an increased risk for severe cytokine release syndrome. In vivo CAR T generation relies on T cell-specific vectors as off-the-shelf product while proof for clinical benefit remains to be provided.
mRNA Delivered In Vivo CAR for Myeloid Cells to Combat Solid Tumors
Yuxiao Wang, PhD, Co-Founder & Vice President, Discovery Research, Myeloid Therapeutics
We introduce a novel class of innate immune receptor-based CARs designed to program myeloid cells in vivo using mRNA/LNP, overcoming limitations of current CAR therapies in solid tumors. Preclinical data demonstrate robust anti-tumor efficacy, leading to the initiation of first-in-human clinical trials for TROP2 and GPC3-targeting CARs, highlighting significant potential for advancing cancer immunotherapy.
3:30 pmSponsored Presentation (Opportunity Available)
4:00 pmNetworking Refreshment Break
Engineering Chimeric Antigen Receptor for mRNA CAR T
Huan Yang, PhD, Associate Principal Scientist, Discovery Biologics, Merck & Co. Inc.
Tonic signaling from CAR expression is proposed to be associated with CAR T exhaustion. Our study describes an in vitro model for investigating tonic signaling in mRNA CAR T cells, which has not been fully characterized. Among approximately 80 tested permutations of structural elements, a few optimal CAR designs showed improved antigen-dependent T cell immune responses in vitro. Additionally, several formats of mRNA were also evaluated for CAR expression persistence.
Adaptive Protein Evolution X-attention (APEX) Model for Augmented CAR Discovery
Jenny Wei, PhD, Senior Director, R&D Informatics and Technology, Kite Pharma
To improve the efficiency of design and development of CAR constructs, we built the APEX model by fine tuning protein-language model ESM2 with a dataset comprised of binder (scFv, Fab, and VHH) and antigen pairs curated from the Structural Antibody Database. The model achieved robust performance on affinity prediction and can be expanded for other property prediction. Model adoption into CAR campaign facilitates binder prioritization to reduce discovery cycle time.
5:30 pmPresentation to be Announced
6:00 pmClose of Day
Friday, May 16
7:15 amRegistration Open
INTERACTIVE DISCUSSIONS
Interactive Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Discussions page on the conference website for a complete listing of topics and descriptions.
ML to Optimize Immune Cell Engagers
Winston Haynes, PhD, Head, Data Science & Machine Learning, LabGenius Ltd.
- Dive into the challenges with engineering immune cell engagers where machine learning might have an impact (i.e. development speed, therapeutic efficacy, clinical safety)
- Discuss the data and models needed to develop superior therapies.
- Highlight different machine learning methods being applied to the design and optimisation of immune cell engagers.
- Explore future directions for machine learning in immune cell engagers.
COMPUTATIONAL AND ML APPROACHES TO T CELL ENGAGERS
Next-Generation Immunotherapies Unlocked via Petabyte-Scale Analyses
Caleb A. Lareau, PhD, Assistant Professor, Memorial Sloan Kettering Cancer Center
The accumulation of biological data, including DNA sequencing data in the Sequence Read Archive (SRA) and protein structures in the Protein Data Base (PDB) are the primary substrates underlying recent advances in the use of artificial intelligence in biological systems. Here, we present our lab's recent work on both mining and extrapolating from these repositories of petabyte-scale data, including our identification of potential new modalities for immunotherapy.
Leveraging Single-Cell Sequencing to Identify Highly Precise T-Cell Engager Targets
Alexander J Martinko, PhD, Senior Director, Antibody Engineering & Design, Cartography Biosciences Inc.
T-cell engagers (TCEs) are a promising approach for solid tumors, with the first TCE for a major solid tumor approved in 2024. However, progress is limited by a lack of tumor-selective targets that maximize efficacy while minimizing on-target, off-tumor toxicity. We developed the ATLAS platform, a curated single-cell RNA sequencing resource that leverages both healthy and tumor-derived datasets to identify highly precise TCE targets. Using ATLAS, we discovered LY6G6D as a tumor-specific colorectal cancer (CRC) target, guiding the engineering of a best-in-class LY6G6D TCE for CRC.
Bispecific T Cell Engager Targeting a Novel pHLA Target
Ryan L. Stafford, PhD, Executive Director, Protein Engineering, 3T Biosciences Inc.
T cells recognize intracellular targets presented by HLA to enable potent anti-tumor immune responses, and these targets can be leveraged to generate off-the-shelf therapeutics using T cell-bispecific engagers to treat a broad patient population. We've developed 3T-TRACE to rapidly identify the antigens of orphan T cells from patient tumors and 3T-PRIME, a TCR mimetic platform to rapidly generate potent and specific binders for therapeutic development.
10:00 amSponsored Presentation (Opportunity Available)
10:30 amNetworking Coffee Break
A Novel T Cell Engager Platform Empowering Innovative and Effective Immunotherapies
Ahmet S. Vakkasoglu, PhD, Associate Director, Biologics Discovery and Innovation, Cue Biopharma
Immuno-STATs represent a Fc fusion molecules capable of engaging, activating, and amplifying disease-specific T-cells. Our leading clinical candidate, CUE-101, specifically targets HPV E7-specific T cells and has shown remarkable efficacy in patients with advanced head and neck cancer. With this clinical success and our platform's proven safety, we introduce the Immuno-STAT platform. It enables the targeting of various tumor types in addition to AI applications.
Non-Pathogenic E. coli Displaying Decoy-Resistant IL18 Mutein Boosts Antitumor and CAR NK Cell Responses
Jiahe Li, PhD, Assistant Professor, Biomedical Engineering, University of Michigan
The tumor microenvironment can inhibit the efficacy of cancer therapies through mechanisms such as poor trafficking and exhaustion of immune cells. Here, to address this challenge, we exploited the safety, tumor tropism and ease of genetic manipulation of non-pathogenic Escherichia coli (E. coli) to deliver key immune-activating cytokines to tumors via surface display on the outer membrane of E. coli K-12 DH5a.
Cancer-Specific Targeting of Vesicular Stomatitis Virus
Kepeng Wang, PhD, Assistant Professor, Department of Immunology, University of Connecticut
Oncolytic viral therapies for cancers are frequently limited to intralesional injection due to non-specific localization of systemically injected viral particles. We developed a modified vesicular stomatitis virus (VSV) that harbors tumor-activating moiety. This novel virus preferentially distributes to tumor tissues and showed enhanced safety compared to wild-type VSV. When incorporated with a single chain, biologically active interleukin-12 (IL-12)-the novel virus mounts effective control against tumor growth.
12:30 pmClose of Summit
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。
アジェンダ・講演者・スポンサー更新
2025年 プログラム
表示する:

工学ストリーム

腫瘍ストリーム

多重特異性ストリーム

免疫療法ストリーム

発現ストリーム

分析法ストリーム

免疫原性ストリーム

新興治療ストリーム

機械学習ストリーム